RxDoctor Payments Data

Afshin Adhami, MD

Internal Medicine · El Monte, CANPI 1104991686

Payments from drug & device makers

$2,249in general payments, 2019–2025

Across 110 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$513
  • Amgen$397
  • Merck$262
  • Novo Nordisk$206
  • AstraZeneca$159
  • AbbVie$122
  • plus $591 from 13 others

What the payments were for

  • Speaking & faculty fees$593%
  • Food & beverage$2,16796%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,249 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$187,761
Medicare patients
171
Services billed
2,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$137,706
RybelsusSemaglutide38$75,759
JanuviaSitagliptin Phosphate61$60,304
BiktarvyBictegrav/Emtricit/Tenofov Ala13$46,052
MounjaroTirzepatide36$39,279
FarxigaDapagliflozin Propanediol33$38,545
JardianceEmpagliflozin23$33,059
EliquisApixaban31$26,768
Combivent RespimatIpratropium/Albuterol Sulfate27$22,730
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$21,392
MyrbetriqMirabegron14$18,073
XareltoRivaroxaban12$14,461
Ondansetron Hcl24$5,486
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,555
LantusInsulin Glargine,hum.Rec.Anlog11$4,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$206$213,465141 claims
MerckJanuvia$262$60,30461 claims
Boehringer IngelheimJardiance, Combivent Respimat$73$55,78950 claims
Lilly USA, LLCMounjaro$513$39,27936 claims
AstraZenecaFarxiga$159$38,54533 claims
PfizerEliquis$79$26,76831 claims
GSKTrelegy Ellipta$25$21,39226 claims
Johnson & JohnsonXarelto$110$14,46112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in El Monte

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →